Indication:
Lenvatinib is prescribed primarily for treating differentiated thyroid cancer (DTC), renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC).

Pharmacology:
Lenvatinib blocks various receptor tyrosine kinases that play a role in tumor growth, angiogenesis, and cancer cell proliferation.

Dosage and Administration:
The dosage varies depending on the patient’s condition and response to treatment. Typically, it’s taken orally once daily, with or without food, as per the doctor’s instructions.

Interactions:
Lenvatinib can interact with several medications, including other cancer drugs, certain antibiotics, antifungals, and drugs metabolized by the liver. Patients should inform their doctor about all medications and supplements they are taking.

Side Effects:
Common side effects encompass hypertension, fatigue, diarrhea, decreased appetite, weight loss, proteinuria, and nausea. Serious adverse effects may involve liver issues, bleeding, gastrointestinal problems, cardiovascular events, and renal failure.

6. **Precautions and Warnings**:
– Patients with hypertension should have their blood pressure managed before starting Lenvatinib. Regular monitoring of blood pressure, liver, and kidney function is vital during treatment. Caution is warranted in patients with a history of cardiovascular disease or gastrointestinal disorders. Pregnant or breastfeeding women should avoid Lenvatinib due to potential harm to the fetus or newborn.

7. **Overdose Effects**:
– Overdose may lead to exacerbated adverse reactions like severe hypertension, gastrointestinal symptoms, and liver toxicity. Management typically involves supportive measures, symptomatic treatment, and close monitoring of vital signs and organ function.